Biogen’s stock increased by 1% on Thursday following a positive opinion from Europe’s pharmaceutical regulator regarding their Alzheimer’s disease drug developed with Eisai. This decision reversed a previous ruling that had initially denied approval for the drug, indicating a positive shift in the regulatory landscape for the medication. The news of the favorable opinion boosted investor confidence and contributed to the rise in Biogen’s stock value.
Full Article
C. Richard Kramlich, Early Investor in Silicon Valley, Dies at 89
C. Richard Kramlich, a pioneering investor in Silicon Valley and co-founder of New Enterprise Associates, passed away at 89 in Oakville, Calif. Known for backing tech giants like Apple and Juniper Networks, he grew NEA from a $16 million fund to $26 billion, emphasizing the importance of relationships in venture capital. His legacy includes mentoring founders, investing in emerging technologies, and amassing a significant art collection with his wife, Pamela, showcasing his commitment to innovation...
Read more